Clinical Trial Detail

NCT ID NCT04227028
Title Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Northwestern University
Indications

lung non-small cell carcinoma

Therapies

Bevacizumab + Brigatinib

Age Groups: adult senior

Additional content available in CKB BOOST